View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
October 31, 2012

Cubist begins patient enrolment in Phase III CB-5945 OIC ascent programme

Cubist Pharmaceuticals has commenced patient enrolment in its Phase III CB-5945 Ascent study for the treatment of opioid-induced constipation (OIC).

Cubist Pharmaceuticals has commenced patient enrolment in its Phase III CB-5945 ascent study for the treatment of opioid-induced constipation (OIC).

The multicentre, long-term safety study is one of four registrational studies conducted in patients with chronic non-cancer pain.

The randomised (1:1), double-blind, placebo-controlled study is designed to evaluate CB-5945 (0.25mg twice a day) and will enrol 1,400 eligible patients in the US and Canada.

Cubist chief scientific officer Dr Steve Gilman said that for millions of people with chronic non-cancer pain, opioid-induced constipation is a debilitating side effect.

"For millions of people with chronic non-cancer pain, opioid-induced constipation is a debilitating side effect."

"We are excited to begin the robust Phase III development program for CB-5945 and hope one day to make this important therapy available for patients," Gilman said.

The safety of CB-5945 (0.25mg twice a day) compared with placebo over a one-year treatment period is the primary objective of the study, while the effects of the candidate on quality of life is a secondary objective.

A total of nearly 3,200 patients are expected to be enrolled in the Phase III programme.

CB-5945 is a potent, peripherally acting mu opioid receptor antagonist designed to block the adverse effects of opioid analgesics on the gastrointestinal tract without affecting the centrally mediated pain relief.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena